Hear from Others about CEL-SCI

The following is a compilation of letters from some of our supporters that we would like to share with you.

If you would like to share your feedback with us, we invite you to send us your comments or letters to Feedback@cel-sci.com. Please indicate if you would like to post your letter publicly on our website to share with others.


	o	Individual Investor, January 2010 "I just wanted to express again my appreciation for the phenomenal tour and discussions our group had yesterday. To say that we were all shocked by the facility would be an understatement. Keep up all the hard work and you will truly make the world a better place. Thanks again."
	o	Individual Investor, October 2009 "I've been a shareholder for several years. I just wanted to write a note to congratulate you and the rest of the team on our recent success and to thank you for all of your hard work. The last couple of months have been a wild ride and I think it's going to get even more exciting. Please express my gratitude to the rest of the team. Thanks again."

	o	Individual Investor, September 2009 "I am a stockholder and am very proud of it. I just wanted to say that you & your team are brilliant."

	o	Individual Investor, September 2009 "Now I know why CVM wasn't at their (Rodman & Renshaw) conference!! Good news Gavin...you guys have the money to do what you need to do now.....get P3 started, and get H1N1 going...good job to all of you!!"

	o	Individual Investor, August 2008 “With over 100,000 shares of trust in Geert and Max in my personal investment portfolio I am excited to learn of the progress made by staff. I love the fact that this company has been under the radar of many individual investors and portfolio managers. This "stealth effect" has allowed myself and other believers in the company and its technologies to accumulate shares over time at bargain prices .It is not often the individual investor is offered the opportunity to "beat the street" and purchase shares, in a company that offers such promise prior to large mutual funds and investment groups inflating the share price after they have taken a position. Let us not forget however that monetary gains may be the gold standard for investors but saving lives and removing burden from the public and private health care sector is the most rewarding of goals and I for one am proud for being a small of the solution. In closing I wish to thank management and staff for their hard work, dedication and achieved goals. After all is not the ultimate endpoint the smile of a cancer SURVIVOR?”

	o	Individual Investor, November 2007 "I think the company is doing fantastic job in getting itself known. I've been a shareholder for around five years and presently own 165,000 shares and plan on adding more weekly because I believe in the drugs and hope that it is approved because of the need for cancer without all those side effects."

	o	Individual Investor and Radiation Oncologist, June 2007 "Geert Kersten's letter to the shareholders was an excellent, clear summary of the science of Multikine® with allusions to a fantastic future. I believe in that future. I presently own 150,000 shares in my personal and pension accounts and have no intention of selling anytime soon. I am a Diagnostic Radiologist, Chairman of the Cancer Care Committee at my institution, and a cancer survivor in remission for three years. I wish something like Multikine® was available for me prior to my neo-adjuvant chemotherapy and radiation therapy, surgery, and follow-up adjuvant chemotherapy. Once the Phase III trial is successful and FDA approval occurs, I believe there will be multiple centers researching this new concept of immune system activation prior to other therapies for all solid tumors, not just head & neck, prostate, or cervical neoplasia. I would much rather see all patients getting a chance for their own immune system to sensitize the cancer to the burn and poison of radiation and chemotherapy then to undergo these therapies, have a recurrence, and then to undergo salvage therapy. With Multikine®, fewer patients should get a recurrence, and with the pre-sensitization of the tumor, the course of radiation and/or chemotherapy could be shortened, decreasing the side effects of these therapies. The future looks extremely bright, and this does not even take into account another potential blockbuster therapy, Cel-1000. I plan to be along for the ride."

	o	Individual Investor, June 2007 "In my modest way, I have been heavily invested in CEL-SCI for more than ten years (initially symboled as HIV). I survived and maintained my positions through a great deal of volatility during this period. I stuck with the company as I sincerely believe that new treatments are desperately needed. "Conventional" treatments may be in a loosing battle. Disease mutations are continually becoming more tolerant to existing medications and new threats continue to appear very quickly. Response times to these changes are not rapid nor are the solutions long lasting. The best approach is to let our own natural systems react to these new threats--and with help, I believe they can. CEL-SCI appears to be on the right track. While their initial objective was to treat other "incurable" diseases such as HIV, with further research it became apparent that if successful, the immune enhancement approach can work for almost any abnormality our bodies face. This very well might be a significant fresh beginning."

	o	Individual Investor, October 2007 "I was made aware of CEL-SCI by another Healthcare Professional several years ago. I watched and read before I invested. I was very impressed with the progress that Multikine® showed in its trials. Everyone we know has dealt with cancer in a friend, a colleague, family member or possibly even themselves. The enormously positive news from the Phase II trials had me investing more. I want to see the company and the drug succeed so we can begin to put a serious effort on managing head and neck cancer. It would be disingenuous for me to say that the monetary benefits are not important also. I plan to invest more as I can because I believe within the next 2 years, this company will be on everybody's radar screen. We are taking the time and going through the regulatory motions necessary to make this company and drug a potential blockbuster!"

	o	Individual Investor, June 2007 "Regarding my long-term interest in CEL-SCI Corporation, like far too many families both here and abroad, our family has been directly affected by cancer. Breast, prostate, and skin cancers became personal challenges our family has had to overcome. New treatments and drugs- along with unbending faith- have helped our loved ones recover. Small, courageous research companies like CEL-SCI represent the most basic levels of hope and commitment for those seeking innovative health care choices in dealing with illness and disease. CEL-SCI's research tracks represent the cutting edge of recent insights and advances in immunotherapy treatment. Multikine®, CEL-SCI's proprietary main project, begins with the concept that our own immune systems play an integral role in our treatment success. Multikine® helps the body heal and re-balance itself, an approach that is gaining the public's interest as new, effective and non-toxic options are reporting good developmental progress. CEL-SCI's recent regulatory milestones only make the case for the future even stronger. CEL-SCI's managers have persevered against almost impossible odds, remaining goal-focused through some very difficult, frustrating markets, and successfully moving forward a very important and innovative cancer treatment, a drug that ultimately could affect millions of lives and families. I have been a supporter of this research for over a decade now, and have never felt more positive. Onward and upward for Multikine® and CEL-SCI's other promising projects!"

	o	Individual Investor, June 2007 "Greetings. Let me start off this way: Congratulations! Brilliant work! I have nothing but good things to say about the company. For the company, for that matter as a publicly trading company, it's been rough these last several years. But you managed to bypass several hurdles and achieve many goals. And I believe you will continue to do so. I'm an individual investor in the company, and I've invested in several different companies before, I've tuned into many conference calls, and have never heard any more honest, any more straight forward CEO as Mr. Geert Kersten. Those characteristics alone convinced me even more to invest into CVM. I personally want to thank Mr. Kersten myself. And many thanks to all those involved with this great success so far; from every scientist to every single employee. Everyone. Many thanks! I believe the company is headed in the right direction, and more importantly, if Multikine® continues with its success, people- the patients who need it the most, will benefit greatly."

	o	Individual Investor, June 2007 "Go! Go! Go! Not only for supportive shareholders, but for the cancer victims, sincerely hope you and your team will get great positive achievements about Multikine® soon."

Join the Team

Home Page